Consistent safety and tolerability in adults with bipolar I and bipolar II depression across clinical trials1
Most common adverse reactions in 6-week bipolar depression trials1*
CAPLYTA demonstrated safety in 2664 adult patients with schizophrenia and bipolar depression1
*>5% of patients exposed to CAPLYTA and greater than twice the rate of placebo.1
†Dizziness, dizziness postural.1
There was no single adverse reaction leading to discontinuation that occurred at a rate of >2% in patients treated with CAPLYTA1
Antipsychotic drugs have been reported to cause:
- Seizures. Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
- Potential for Cognitive and Motor Impairment. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.
Reference: 1. CAPLYTA prescribing information, 2022.